Acetylcholine receptor targets on cortical pyramidal neurones as targets for Alzheimer's therapy

Neurodegeneration

Volumn 5, Issue 4, 1996, Pages 453-459

  Chessell, Iain P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Alzheimer's disease; Lesion; Muscarinic receptors; Nicotinic receptors; Volkensin

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; CARBACHOL; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; MUSCARINIC M2 RECEPTOR; NICOTINE; NICOTINIC RECEPTOR; PIRENZEPINE; RICIN; SEROTONIN 1A RECEPTOR; VOLKENSIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; BRAIN CORTEX; BRAIN SLICE; CELL COUNT; CELLULAR DISTRIBUTION; CONFERENCE PAPER; CORPUS STRIATUM; NEOCORTEX; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RADIORECEPTOR ASSAY; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION;

EID: 0030498171     PISSN: 10558330     EISSN: None     Source Type: Journal    
DOI: 10.1006/neur.1996.0062     Document Type: Conference Paper

References (29)

1. Alder JT, Chessell IP, Bowen DM (1995) A neurochemical approach for studying responses to acetylcholine in Alzheimer's disease. Neurochem Res 20:769-771
2. Bowen DM, Francis PT, Pangalos MN, Stephens PH, Procter AW, Chessell IP (1992) 'Traditional' pharmacotherapy may succeed in Alzheimer's disease. Trends Neurosci 15:85
3. Bowen DM, Francis PT, Chessell IP, Webster M (1994) Neurotransmission - the link integrating Alzheimer research? Trends Neurosci 17:149-150
4. Bowen DM, Francis PT, Chessell IP, Webster M, Chen CPL, Qume M, Neary D, Cross AJ, Green AR (1994) Alzheimer's disease: Is the improvement of cholinergic transmission the correct strategy? In Cutler NR, Gottfries CG, Siegfried KR (eds). Alzheimer's Disease: Clinical and treatment aspects, John Wiley & Sons Ltd, Chichester, pp 89-116
5. Chessell IP, Francis PT, Bowen DM (1995) Changes in cortical nicotinic receptor numbers following unilateral destruction of pyramidal neurones by instrastriatal volkensin injection. Neurodegeneration 4:415-424
6. 1) and other neurotransmitter receptors on corticofugal-projecting pyramidal neurones. Brain Res 632:86-94
7. Chessell IP, Francis PT, Webster M, Procter AW, Heath PR, Pearson RCA, Bowen DM (1994) An aspect of Alzheimer neuropathology after suicide-transport damage. J Neural Transm 44[Suppl]:231-243
8. Chessell IP, Humphrey PPA (1995) Nicotinic and muscarinic receptor-evoked depolarizations recorded from a novel cortical brain slice preparation. Neuropharmacology 34:1289-1296
9. 2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin. J Pharmacol Exp Ther 261:1273-1281
10. Francis PT, Sims NR, Procter AW, Bowen DM (1993) Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives. J Neurochem 60:1589-1604
11. Giacobini E (1990) The cholinergic system in Alzheimer disease. Prog Brain Res 84:321-332
12. Greenwood AF, Powers RE, Jope RS (1995) Phosphoinositide hydrolysis, G-alpha-q, phospholipase-C and protein kinase-C in post-mortem human brain-effects of post-mortem interval, subject age, and Alzheimer's disease. Neuroscience 69:125-138
13. Jope RS, Song L, Li X, Powers R (1994) Impaired phosphoinositide hydrolysis in Alzheimer's disease brain. Neurobiol Aging 15:221-226
14. Marks MJ, Stitzel JA, Collins AC (1987) Influence of kinetics of nicotine administration on tolerance development and receptor levels. Pharmacol Biochem Behav 27:505-512
15. McCormick DA, Williamson A (1989) Convergence and divergence of neurotransmitter action in human cerebral cortex. Proc Natl Acad Sci USA 86:8098-8102
16. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH (1992) Release of Alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors. Science 258:304-307
17. Nordberg A, Lilja A, Lundqvist H, Hartvig P, Amberla K, Viitanen M, Warpman U, Johansson M (1992) Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualised by positron emission tomography. Neurobiol Aging 13:747-758
18. 3H] L-689,560 are present but not enriched on corticofugal-projecting pyramidal neurones. Brain Res 596:223-230
19. Pangalos MN, Francis PT, Middlemiss DN, Pearson RCA, Bowen DM (1991) Destruction of a sub-population of cortical neurones by suicide transport of volkensin, a lectin from Adenia volkensii. J Neurosci Meth 40:17-29
20. Pearce BD, Potter LT (1991) Coupling of m1 muscarinic receptors to G protein in Alzheimer disease. Alzheimer Dis Assoc Disord 5:163-172
21. Perry EK, Smith CJ, Court JA, Perry RH (1990) Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types. J Neural Transm P-D Sect 2:149-158
22. Romanelli L, Ohman D, Adem A, Nordberg A (1988) Subchronic treatment of rats with nicotine: interconversion of nicotinic receptor subtypes in brain. Eur J Pharmacol 148:289-291
23. Sadot E, Gurwitz D, Barg J, Behar L, Ginzberg I, Fisher A (1996) Activation of m1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells. J Neurochem 66:877-880
24. Shimohama S, Fujimoto S, Taniguchi T, Kimura J (1992) Phosphotidylinositol-specific phospholipase C activity in the postmortem human brain: no alteration in Alzheimer's disease. Brain Res 579:347-349
25. Whitehouse PJ (1987) Neurotransmitter receptor alterations in Alzheimer disease: a review. Alzheimer Dis Assoc Disord 1:9-18
26. Wiley RG (1992) Neural lesioning with ribosome-inactivating proteins: suicide transport and immunolesioning. Trends Neurosci 15:285-290
27. Wiley RG, Stirpe F (1988) Modeccin and volkensin but not abrin are effective suicide transport agents in rat CNS. Brain Res 438:145-154
28. Young AB, Penney JB (1994) Neurotransmitter receptors in Alzheimer disease. In Terry RD, Katzman R, Bick KL (eds). Alzheimer Disease, Raven Press, New York, pp 293-303
29. Zilles K (1985) The cortex of the rat. Springer-Verlag, Berlin